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Abstract: Systemic lupus erythematosus (SLE) is characterised by increased mortality secondary to cardiovascular diseases (CVD). Despite being common in SLE, traditional cardiovascular risk factors cannot entirely justify such increase in CVD-associated mortality. The endothelium is a key regulator of the vascular homeostasis; lupus-associated persistent systemic inflammation may impair endothelium functionality, thus initiating a cascade of events that, in concert with traditional CVD-risk factors, leads to atherosclerosis development and progression. Numerous methods have been used for the in vivo assessment of the endothelial function; among all, flow-mediated dilatation (FMD) has been widely validated in clinical trials. Quantification of the endothelial dysfunction by FMD has been confirmed to be an early predictor of CVD in multiple studies involving both non-CVD and CVD-population and it may therefore represent a likewise efficient biomarker of CVD in SLE. To date, the vast majority of the available data, albeit not all, shows that endothelium-dependent FMD values are indeed lower in SLE patients compared to healthy subjects; further studies, however, will be required in order to confirm the usefulness of the endothelial dysfunction quantification as CVD-predictor in the specific clinical setting of lupus. Notably, FMD variations can also be a sensitive marker for assessing specific therapeutic strategies ability of improving endothelial function in SLE patients. 
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1.	INTRODUCTION
Systemic lupus erythematosus (SLE), similarly to other inflammatory autoimmune diseases (IAD) like systemic sclerosis (SSc), psoriatic arthritis (PsA) and rheumatoid arthritis (RA), is characterised by raised mortality rate secondary to cardiovascular diseases (CVD). For instance, the risk of death for CVD in RA is comparable in magnitude to the one associated with type 2 diabetes mellitus (T2DM) [1]–[5]. Traditional cardiovascular risk factors e.g. dyslipidaemia and hypertension, despite being common in SLE, cannot fully explain such increase in CVD-associated mortality [1], [2], [6]–[8].
The scoring system used for cardiovascular risk stratification in the general population is therefore not sensitive enough for early detection of CVD risk in rheumatic patients [9], [10]; the European League Against Rheumatic Diseases (EULAR) has recognised this unmet clinical need and has called for the development of novel specific cardiovascular risk stratification strategies [11], [12]. 
Atherosclerosis, a hallmark of CVD, is premature and accelerated in SLE [10]. The underlying inflammatory autoimmune process can indeed further amplify the low-grade inflammation associated with atherosclerosis [13], [14]; hence, while the chronic inflammatory milieu emerges in endothelial cells, it contributes to the endothelial dysfunction (ED) development [2]. The dysfunctional endothelium constitutes a key early-event in the progression of the atherosclerotic plaques, and it has been therefore proposed as a “barometer” for cardiovascular risk, especially because of its ability to take into accounts also non-traditional and/or unknown risk factors [15], [16] potentially playing an important role in SLE. Following its remarkable spreading of use and its clinically proven diagnostic/prognostic power as CVD predictor in T2DM and hypertension, endothelial dysfunction assessment has been proposed to be an early marker of CVD-risk also in IAD [17], [18].  
In this review, we aim to summarise the most common non-invasive methods of endothelial function assessment, to offer a concise overview of the evidence available about the endothelial function in SLE patients and to discuss the most recent clinical trials evaluating the effects of commonly used therapeutics on the endothelial function.




1.1.	Pathogenesis of the endothelial dysfunction
The endothelium finely regulates vascular homeostasis in all its complexity by controlling vascular tone, coagulation status, platelets aggregation and vascular smooth muscle cells (VSMCs) proliferation [19]. 
The highly metabolically active endothelial cells promptly respond to a plethora of activating physical and chemical stimuli by secreting vasoactive molecules, primarily nitric oxide (NO); this is produced through the enzymatic conversion of the L-arginine by endothelial NO-synthase (eNOS) [20]. Additional molecules contribute to the vascular homeostasis too: for instance, regulators of the vascular tone (e.g. prostacyclin, bradykinin, endothelin), growth factors, coagulation factors and immunological molecules such as intercellular adhesion molecules (ICAMs), vascular cell adhesion molecules (VCAMs), monocyte chemotactic protein 1 (MCP-1 or CCL2) and tumor necrosis factor (TNF) [18], [21]. 
Vascular endothelium dysfunction and injuries are considered preliminary events in atherosclerosis and, overall, in several common vascular diseases [22]. In “dysfunctional” conditions, the reduced availability of NO facilitates vasoconstriction, leukocyte adhesion, platelets aggregation and VSMCs proliferation; afterwards, raised vascular permeability, accumulation of lipids and recruitment of immune cells follow these preliminary events [22], [23]. For instance, T cells and monocytes have been demonstrated to infiltrate both the damaged endothelium and the atherosclerotic lesions leading to the local overproduction of pro-inflammatory mediators e.g. TNF, IL-6 and IL-1 [18], [19], [24]. 
Systemic inflammation, which is a typical feature of IAD, may be conducive to the establishment and progression of vascular inflammation, acting synergically with the traditional CVD risk factors (e.g. smoking, hypertension, obesity, dyslipidaemia, ageing). Patients experiencing CVD have significantly higher circulating levels of TNF-α; TNF-α itself can be pathogenic and directly impair the endothelial function by triggering NF-κB signalling activation, reducing NOS expression and stimulating the production of reactive oxygen species (ROS) in endothelial cells [19], [25]. These considerations are equally valid for other pleiotropic cytokines such as IL-6 and IL-1 [19], [26]. Notably, compelling evidence, largely coming from rheumatoid arthritis, is revealing that biologic agents targeting pro-inflammatory cytokines such as TNF, IL6 and IL-1 and rituximab, targeting B cells have beneficial effects on the endothelial function [27]–[30]. 

Persistence of chronic inflammation within the blood vessels facilitates the endothelial overexpression of adhesion molecules such as VCAMs and ICAMs, worsening the ED beyond; interestingly, soluble VCAM seems to be a sensitive biomarker of response to therapy in SLE [2], [25], [31]. C-reactive protein (CRP), a serum acute-phase reactant produced in response to inflammation, not only has a predictive value for cardiovascular risk but also plays a direct pathogenic role being able to induce oxidative stress and impairment in NO production [32], [33].
1.2.	Measures of endothelial function
Several techniques have been used for the in vivo evaluation of the endothelial function; among all, flow-mediated dilatation (FMD), venous occlusion plethysmography (VOP), peripheral arterial tonometry (PAT) and laser doppler iontophoresis (LDI) have been widely validated in clinical studies. 
FMD [34] evaluates the arteries ability of responding to the induction of flow-mediated reactive hyperaemia (by occluding the brachial artery with an inflatable blood pressure cuff for 5 minutes) with endothelial NO release. A quantification of the endothelial function is obtained by measuring with an ultrasound (US) machine the diameter of brachial artery before and after the induction of reactive hyperaemia. While this test evaluates the endothelium-dependent FMD, a similar one is used for assessing the endothelium-independent FMD: in this case, the forearm occlusion is substituted by the administration of a source of NO (i.e. nitroglycerin). In this condition, the test acquires a different biological value as the production of endothelial NO is abrogated by the exogenous NO administration and therefore the main determinant of the vascular wall response is the activity of the vascular musculature.
VOP [35] is based on the principle that the interruption of venous outflow from the forearm maintaining an unaltered arterial flow determines an increase in the forearm volume that, ideally, correlates with the forearm vascular resistance, which is an indirect measure of the endothelial function. Changes in the forearm volume are measured by plethysmography; medications can be given intra-arterially by placing a fine needle into the brachial artery to study the local effects of vasoactive mediators.
PAT [36] evaluates the endothelium-mediated vascular changes quantifying with a pair of plethysmographic probes situated on the index fingertips of each hand the waveform and amplitude of the pulse, both in basal conditions and during the post-reactive hyperaemia phase (obtained occluding the blood flow through the brachial artery for 5 minutes using an inflatable blood pressure cuff) 
LDI [37] is a non-invasive technique for transdermal delivery of a vasoactive substance, occurring for this purpose into the forearm’s skin.  Subsequent alterations in skin blood flow (related to microvascular endothelial function) are detected using a laser doppler imaging method. Among the vasoactive drugs, acetylcholine and sodium nitroprusside are respectively used to generate endothelium-dependent and endothelium-independent vasodilatation.

2.	ENDOTHELIAL DYSFUNCTION in sle
The great interest in the identification of a sensitive biomarker of preclinical atherosclerosis prompted the delivery of several clinical trials aiming at investigating the endothelial function in SLE, utilising the FMD as quantification method. Overall, most of the published data shows lower FMD values in SLE patients in comparison with healthy controls; in a few exceptions this result was not confirmed, probably due to the low power of the study or confounding factors (mainly sex, age and disease activity). 
Two recent meta-analyses pooled data respectively from 1.199 SLE versus 781 healthy controls (HC) and from 580 versus 381 HC [38], [39]. Despite a marked heterogeneity in terms of study designs and features of the study population, both studies confirmed a meaningful reduction of the FMD in SLE patients compared to healthy subjects (FMD -1.19 versus -0.832). Metaregression of other factors revealed that only age and disease duration significantly reduced the gap in terms of FMD between SLE and HC [38]. Variations in the endothelial function were specifically supported by the endothelium-dependent FMD; in fact, the endothelium-independent FMD was preserved in SLE suggesting that, at least in the initial phases of the disease, there is a primary endothelium involvement rather than dysfunction and/or morphological alterations of the vascular smooth-muscle compartment [38]. Hence, endothelial dysfunction is likely to represent a very early sign of vascular disease and to be potentially useful in CVD-risk stratification. The defects in FMD characterising SLE patients might also be related to the frequent presence of antiphospholipid syndrome; this condition, indeed, seems to mediate an impairment of the NO-induced vasodilatation, suggesting either a more aggressive involvement of the endothelium or a preferential damage to the vascular smooth muscle wall [38]. More recently, a cross-sectional study including 100 SLE patients showed that in patients affected by lupus nephritis the FMD values were significantly lower and inversely correlated with age, blood urea and urine albumin [40]. Conversely, a relatively small prospective study including 38 SLE patients failed to confirm FMD as a valid predictor of a composite outcome of health, CV and renal events [41].
In conclusion, while the prognostic value of FMD as early marker of cardiovascular risk has repeatedly been demonstrated in multiple clinical studies involving both non-CVD and CVD-population [42], further trials will be needed to confirm its utility in the specific clinical setting of SLE patients. 

3.	Therapeutic strategies targeting endothelial function
The FMD represents not only a useful early predictor of CVD but, due to its reversibility, it can also be a sensitive parameter for monitoring the efficacy of cardiovascular risk prevention strategies and, possibly, the favorable effect of SLE treatment on endothelial function improvement and atherosclerosis control. The body of evidence on therapeutic interventions targeting the endothelial function is constantly growing; here, we will specifically focus on trials performed on SLE patients.

3.1.	Physical activity
Physical inactivity represents a major CVD risk factor for both the general and the SLE population; in the latter, the concomitant presence of depression, arthritis/arthralgia and fatigue further contributes to the reduced exercise habit [43]. Notably, the difference in FMD between lupus patients and healthy subjects is lost in SLE patients who are physically active [44]. A 16-weeks interventional study on 40 SLE patients demonstrated that supervised physical activity is safe and effective in improving endothelial function and aerobic capacity [45].
3.2.	Hydroxychloroquine
The antimalarial hydroxychloroquine (HCQ), included in the current standard therapy of SLE, contributes to the control of the disease activity and the prevention of the organ damage [46]. Treatment with HCQ shows a beneficial effect on lipid profile in SLE patients and correlates with a reduced CV risk [47]–[49]. The observed reduction of the vascular stiffness and preservation of the vascular elasticity as well as the down-regulation of the endothelin-1, overall support a protective effect of HCQ on the vascular wall [50],[51]; nevertheless, whether or not HCQ preserves the endothelial function in lupus patients has not been fully investigated yet. Available evidence comes mainly from studies in animal models of SLE in which HCQ was able to improve the endothelial function by suppressing the ROS production [52], [53].
3.3.	Statins
Statins are therapeutic agents able to control the plasma level of lipids by inhibiting the hydroxy-methyl-glutaryl-coenzyme-A (HMG-CoA) reductase. Whereas in the past they were especially well-known solely for their role in treating dyslipidaemia, nowadays they are recognised as pleiotropic agents with wide regulatory effects on vasoreactivity, angiotensin-II receptor expression, oxidative stress and platelets activation; notably, they are also immunomodulatory molecules with anti-inflammatory effects [54], being able for instance to modulate TNF-α, IL-6 and ICAM-1 expression, NF-kB activation and Th1 cells-differentiation [55], [56]. Therefore, a possible use of statins as adjuvant therapy in inflammatory diseases has been explored, however with controversial results [57], [58]. An 8-weeks interventional study with atorvastatin showed an improvement of the FMD independently of the presence of conventional CVD risk factors. Analogous results have also been described for the combination pravastatin plus ezetimibe [59] [60]. Nonetheless, a definite confirmation of the efficacy of statins in CV events prevention in SLE is still missing and object of currently ongoing clinical trials [61]. 
3.4.	ACE inhibitors
The renin-angiotensin system (RAS) is one the main therapeutic target in the management of hypertension and the prevention of cardiovascular events. Angiotensin-converting enzyme inhibitors (ACEi) exert their pharmacological activity on one hand by reducing the production of angiotensin II,  a potent vasoconstrictor, and, on the other, by preserving the amount of bradykinin, a vasodilating mediator [62]–[64]. Similarly to statins, also ACEi seem to have anti-inflammatory effects, which are likely to play an additional role in reducing atherosclerosis. Some ACEi can indeed lessen the production of ROS and the expression of adhesion molecules (e.g. VCAM-1 and ICAM-1) [63]. It is not surprising though that ACE inhibition may be effective in improving the endothelial dysfunction, as already confirmed in clinical trials involving RA patients [65]. Specific data on SLE population are missing, but trials aiming at defining the ACEi efficacy in modulating endothelial function in these patients are warranted.  
3.5.	Omega-3 polyunsaturated fatty acids 
Omega-3 polyunsaturated fatty acids (Ω-3 PUFA) raised interest because of their pleiotropic activity in preventing atherosclerosis; even if the dietary supplementation of Ω-3 PUFA is currently recommended based on the results of the pre-clinical data [66]–[68], a conclusive evidence of the real clinical benefit is still debated [66]. Wright et al conducted a 24-week randomized, double-blind placebo-controlled trial on 60 SLE patients investigating the effects of the administration of 3 g/daily of Ω-3 PUFA [69]; they show a significant raise in FMD and, globally, a reduction of the disease activity (consistently with data coming from lupus mouse models) [69]. In contrast, an analogous study involving 85 SLE subjects did not detect differences in FMD and failed to replicate such results [70].
3.6.	Vitamin C and E
Given the central pathogenic role of ROS formation in endothelial damage and cell death [71], [72], the effect of antioxidant compounds have been investigated. A small double-blind placebo-controlled study evaluated the synergistic action of two non-enzymatic ROS scavengers (daily administration of Vitamin C 500 mg and Vitamin E 800 IU) on ROS generation; after 3 months, however, the endothelial function assessed by FMD was not improved [73].
3.7.	Vitamin D
Vitamin D3 (cholecalciferol) is a steroid vitamin whose levels depend on both the nutritional uptake and the UVB-mediated conversion of the precursor 7-dehydro-cholesterol occurring in the skin. To be activated and capable of proficiently binding its receptor, vitamin D3 requires two sequential enzymatic conversions leading to the generation of the 1,25-OH-Vitamin D3 (calcitriol) [74]. Vitamin D3 deficiency is extremely common [75], especially in rheumatologic patients [76], [77]; among them, patients affected by SLE show remarkably low vitamin D3 levels consistently with their photosensitivity [78], [79]. In the general population hypovitaminosis D correlates with endothelial dysfunction and subclinical atherosclerosis [80]–[82]; thus, not surprisingly, it associates with future cardiovascular events [83]. Similarly, low vitamin D3 levels in SLE patients correlate with dysfunctional endothelium, increased aortic stiffness and atherosclerotic burden [84], [85]. The potential pathogenic role of hypovitaminosis D in endothelial dysfunction development in SLE has been recently demonstrated in a murine model of lupus (MRL/lpr) [86]. Whether or not vitamin D3 supplementation is able to improve endothelial function in patients is currently under investigation. Results from a trial conducted on T2DM patients show that a single high dose of vitamin D determined a significant improvement in FMD in comparison with placebo [87]. With regards to SLE patients, data coming from a small interventional trial including 9 lupus patients suggest that oral vitamin D3 administration mediates endothelial function improvement and potentially reduces the CVD risk [88]. Accordingly, a larger study enrolling 40 patients affected by SLE demonstrates that FMD improvement associates with raised vitamin D3 levels after 12 weeks of supplementation [89]. Future trials enrolling a higher number of patients will be required in order to confirm the positive effect of vitamin D on endothelial function. Moreover, since alternative treatment regimens seem to be differentially effective, especially in suppressing the parathyroid hormone (PTH) [90], a common and standardized therapeutic strategy will be essential for comparing clinical trials outcomes.  

CONCLUSION
	Identification of early predictors of CVD in lupus patients is of fundamental importance. Quantification of the endothelial dysfunction by flow-mediated dilatation may represent a valuable tool, however further studies are required. Therapeutic intervention able to restore the endothelial function in SLE patients are currently under investigation. To date, hydroxychloroquine, statins, ACE inhibitors, omega-3 polyunsaturated fatty acids and vitamin D have been explored as potential candidates; nevertheless, future interventional clinical trials are needed for confirming their role. 
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